An open label, randomized, 2 x 3 crossover study to evaluate bioequivalence between fixed-dose combination of SAH100 tablets (300/5/25mg aliskiren/amlodipine/HCTZ) and free combination of market formulation of 300mg aliskiren tablet, and clinical service formulations of 5mg amlodipine and 25mg hydrochlorothiazide in healthy subjects under light meal conditions

Trial Profile

An open label, randomized, 2 x 3 crossover study to evaluate bioequivalence between fixed-dose combination of SAH100 tablets (300/5/25mg aliskiren/amlodipine/HCTZ) and free combination of market formulation of 300mg aliskiren tablet, and clinical service formulations of 5mg amlodipine and 25mg hydrochlorothiazide in healthy subjects under light meal conditions

Not yet recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Aug 2016

At a glance

  • Drugs Aliskiren; Aliskiren/amlodipine/hydrochlorothiazide; Amlodipine; Hydrochlorothiazide
  • Indications Hypertension
  • Focus Pharmacokinetics
  • Sponsors Novartis
  • Most Recent Events

    • 05 Oct 2011 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top